RESUMEN
OBJECTIVES: To assess the impact of neoadjuvant chemoradiotherapy (NCRT) on anastomotic leakage (AL) and other postoperative outcomes after esophageal cancer (EC) resection. BACKGROUND: Conflicting data have emerged from randomized studies regarding the impact of NCRT on AL. METHODS: Among 2944 consecutive patients operated on for EC between 2000 and 2010 in 30 European centers, patients treated by NCRT after surgery (n=593) were compared with those treated by primary surgery (n=1487). Multivariable analyses and propensity score matching were used to compensate for the differences in some baseline characteristics. RESULTS: Patients in the NCRT group were younger, with a higher prevalence of male sex, malnutrition, advanced tumor stage, squamous cell carcinoma, and surgery after 2005 when compared with the primary surgery group. Postoperative AL rates were 8.8% versus 10.6% (P=0.220), and 90-day postoperative mortality and morbidity rates were 9.3% versus 7.2% (P=0.110) and 33.4% versus 32.1% (P=0.564), respectively. Pulmonary complication rates did not differ between groups (24.6% vs 22.5%; P=0.291), whereas chylothorax (2.5% vs 1.2%; P=0.020), cardiovascular complications (8.6% vs 0.1%; P=0.037), and thromboembolic events (8.6% vs 6.0%; P=0.037) were higher in the NCRT group. After propensity score matching, AL rates were 8.8% versus 11.3% (P=0.228), with more chylothorax (2.5% vs 0.7%; P=0.030) and trend toward more cardiovascular and thromboembolic events in the NCRT group (P=0.069). Predictors of AL were high American Society of Anesthesiologists scores, supracarinal tumoral location, and cervical anastomosis, but not NCRT. CONCLUSIONS: Neoadjuvant chemoradiotherapy does not have an impact on the AL rate after EC resection (NCT 01927016).
Asunto(s)
Quimioradioterapia , Neoplasias Esofágicas/terapia , Complicaciones Posoperatorias/epidemiología , Adenocarcinoma/patología , Adenocarcinoma/terapia , Adulto , Anciano , Anciano de 80 o más Años , Fuga Anastomótica/epidemiología , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/terapia , Diagnóstico por Imagen , Neoplasias Esofágicas/patología , Europa (Continente)/epidemiología , Femenino , Humanos , Metástasis Linfática , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante , Puntaje de Propensión , Factores de Riesgo , Resultado del TratamientoRESUMEN
BACKGROUND: Open transthoracic oesophagectomy is the standard treatment for infracarinal resectable oesophageal carcinomas, although it is associated with high mortality and morbidity rates of 2 to 10% and 30 to 50%, respectively, for both the abdominal and thoracic approaches. The worldwide popularity of laparoscopic techniques is based on promising results, including lower postoperative morbidity rates, which are related to the reduced postoperative trauma. We hypothesise that the laparoscopic abdominal approach (laparoscopic gastric mobilisation) in oesophageal cancer surgery will decrease the major postoperative complication rate due to the reduced surgical trauma. METHODS/DESIGN: The MIRO trial is an open, controlled, prospective, randomised multicentre phase III trial. Patients in study arm A will receive laparoscopic-assisted oesophagectomy, i.e., a transthoracic oesophagectomy with two-field lymphadenectomy and laparoscopic gastric mobilisation. Patients in study arm B will receive the same procedure, but with the conventional open abdominal approach. The primary objective of the study is to evaluate the major postoperative 30-day morbidity. Secondary objectives are to assess the overall 30-day morbidity, 30-day mortality, 30-day pulmonary morbidity, disease-free survival, overall survival as well as quality of life and to perform medico-economic analysis. A total of 200 patients will be enrolled, and two safety analyses will be performed using 25 and 50 patients included in arm A. DISCUSSION: Postoperative morbidity remains high after oesophageal cancer surgery, especially due to major pulmonary complications, which are responsible for 50% of the postoperative deaths. This study represents the first randomised controlled phase III trial to evaluate the benefits of the minimally invasive approach with respect to the postoperative course and oncological outcomes in oesophageal cancer surgery. TRIAL REGISTRATION: NCT00937456 (ClinicalTrials.gov).
Asunto(s)
Adenocarcinoma/cirugía , Carcinoma de Células Escamosas/cirugía , Neoplasias Esofágicas/cirugía , Esofagectomía/métodos , Laparoscopía , Adulto , Anciano , Esófago/patología , Esófago/cirugía , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Escisión del Ganglio Linfático , Persona de Mediana Edad , Cuidados Posoperatorios , Cuidados Preoperatorios , Estudios Prospectivos , Estómago/cirugía , Toracotomía , Adulto JovenRESUMEN
Perioperative chemotherapy for gastric cancer is validated by two phase III studies. The impact of the preoperative neoadjuvant sequence is probably major in the benefit of this treatment. This chemotherapy increases the R0 resection without increasing either morbidity or mortality. Furthermore, it reduces local and systemic recurrence improving disease-free survival and overall survival. The drugs used are 5-FU or its oral prodrugs, platinum salts (cisplatin or oxaliplatin) and anthracyclines. The perioperative chemotherapy must be proposed to all patients with a T3 or N+ gastric adenocarcinoma. This requirement imposes a rigorous preoperative evaluation including thoraco-abdominal computed tomography and for all non-metastatic patients an echo-endoscopy with biopsies. For patients not receiving preoperative chemotherapy, multidisciplinary consultations have the choice between an adjuvant chemotherapy based on 5-FU validated by a meta-analysis or a postoperative radio-chemotherapy whose application is validated by this phase III study.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Gástricas/tratamiento farmacológico , Neoplasias Gástricas/cirugía , Quimioterapia Adyuvante , Humanos , Terapia Neoadyuvante , Cuidados Preoperatorios , Neoplasias Gástricas/patologíaRESUMEN
OBJECTIVES: To compare the influence of 2 volumes of fluid, integrated with goal-directed fluid therapy, on hypovolemia (a key trigger of tissue hypoperfusion) and central venous oxygen saturation (Scvo2) and to assess their relationships with postoperative morbidity. DESIGN, SETTING, AND PATIENTS: A prospective, randomized trial of 70 consecutive patients undergoing major abdominal surgery. INTERVENTIONS: Patients were randomly assigned to 6 mL/kg/h of crystalloid (a restrictive fluid strategy) or 12 mL/kg/h of crystalloid (a more conservative fluid strategy). In both groups, a fluid bolus was administered when respiratory variation in peak aortic flow velocity (ΔPV) was greater than 13%. Data on hypovolemia (ΔPV > 13%), Scvo2, and postoperative complications were recorded for all patients. MAIN OUTCOME MEASURES: Overall incidence of postoperative complications, especially anastomotic leak and sepsis. RESULTS: Overall incidence of complications, including postoperative anastomotic leak and sepsis, was higher in the restrictive group than in the conservative group (all P < .05). The number of patients with hypovolemia increased significantly in the restrictive group compared with the conservative group (P < .001). The perioperative mean Scvo2 (P = .02) and mean minimum Scvo2 (P = .04) were significantly lower in the restrictive group than in the conservative group. Multivariate analysis showed that both hypovolemia and mean minimum Scvo2 were independently associated with anastomotic leak and sepsis. CONCLUSIONS: Excessive fluid restriction increased the level of hypovolemia, leading to reduced Scvo2 and thereby increased incidence of postoperative complications. Excessive fluid restriction should be applied cautiously in surgical patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00852449.
Asunto(s)
Abdomen/cirugía , Fluidoterapia/métodos , Mortalidad Hospitalaria/tendencias , Cuidados Intraoperatorios/métodos , Soluciones Isotónicas/uso terapéutico , Oxígeno/sangre , Adulto , Anciano , Análisis de Varianza , Presión Venosa Central , Intervalos de Confianza , Soluciones Cristaloides , Procedimientos Quirúrgicos del Sistema Digestivo/métodos , Femenino , Fluidoterapia/normas , Estudios de Seguimiento , Humanos , Hipovolemia/prevención & control , Laparotomía/efectos adversos , Laparotomía/métodos , Masculino , Persona de Mediana Edad , Monitoreo Fisiológico/métodos , Análisis Multivariante , Oportunidad Relativa , Consumo de Oxígeno/fisiología , Complicaciones Posoperatorias/mortalidad , Complicaciones Posoperatorias/prevención & control , Estudios Prospectivos , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
Hepatic necrosis after ethanol ablation for hepatocellular carcinoma (HCC), although rare, is well known and described, particularly in patients with chronic liver disease. The present report describes a rare case of massive hepatic necrosis with partial gastric, splenic, and pancreatic infarctions after local treatment of liver HCC with ethanol ablation and discusses the reasons for this complication. With the increasing use of percutaneous techniques to treat liver tumors, it is imperative for the interventional radiologist to be aware of the potential vascular complications of these techniques. An appreciation of vascular anatomy via multidetector computed tomography (CT) and/or magnetic resonance (MR) angiography is important when planning image-guided interventions.
Asunto(s)
Carcinoma Hepatocelular/terapia , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Etanol/efectos adversos , Infarto/inducido químicamente , Neoplasias Hepáticas/terapia , Páncreas/irrigación sanguínea , Bazo/irrigación sanguínea , Estómago/irrigación sanguínea , Anciano , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Carcinoma Hepatocelular/irrigación sanguínea , Carcinoma Hepatocelular/diagnóstico por imagen , Enfermedad Hepática Inducida por Sustancias y Drogas/diagnóstico por imagen , Enfermedad Hepática Inducida por Sustancias y Drogas/terapia , Etanol/administración & dosificación , Humanos , Infarto/diagnóstico por imagen , Infarto/terapia , Inyecciones Intralesiones , Neoplasias Hepáticas/irrigación sanguínea , Neoplasias Hepáticas/diagnóstico por imagen , Masculino , Necrosis , Índice de Severidad de la Enfermedad , Tomografía Computarizada por Rayos X , Resultado del TratamientoRESUMEN
BACKGROUND: Pancreatic fistula (PF) is the single most important complication after pancreaticoduodenectomy. Recently, a 0% rate of PF was reported using a binding pancreaticojejunostomy with intussusception of the pancreatic stump. The aim of this study was to assess the safety of this new binding pancreaticojejunostomy in condition most susceptible to PF, i.e. soft pancreas and non-dilated main pancreatic duct. METHODS: Forty-five consecutive patients with soft pancreas and non-dilated main pancreatic duct underwent a binding pancreaticojejunostomy. Post-operative PF was defined according to the International Study Group of Pancreatic Fistula. RESULTS: Four patients (8.9%) developed a PF. In one case, PF developed on post-operative day 3 due to a technical deficiency. In the three other cases, pancreatic fistula developed after the tenth post-operative day; all the patients had local and/or general co-morbidities before PF occurrence. CONCLUSIONS: Binding pancreaticojejunostomy according to Peng is a safe and secure technique that improves the rate of pancreatic fistula, especially in case of soft texture of the pancreas remnant. However, a 0% rate seems to be hard to achieve because other abdominal and general complications are frequent and can lead to secondary leakage of the pancreatic anastomosis.